System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Research Support, Non-U.S. Gov't Ppublish

PubMed: 39101682 DOI: 10.1080/21505594.2024.2387181

Evaluation of the immune responses of biological adjuvant bivalent vaccine with three different insertion modes for ND and IBD.

Virulence 15(1):2387181

Authors: Wenying Sun, Shuang Li, Dun Niu, Ruihan Qin, Huimin Li, Zhiqiang Xue, Yunpeng Guo, Jinmiao Liu, Yijia Liu, Xinghao Jiang, Jiechao Yin, Xiaochen Guo, Guiping Ren

Affiliations

  • Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin, China.
  • Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin, China. Research Center of Genetic Engineering of Pharmaceuticals of Heilongjiang Province, Northeast Agricultural University, Harbin, China. Key Laboratory of Agricultural Biological Functional Gene, Northeast Agricultural University, Harbin, China.

Abstract

Infectious bursal disease (IBD) is a widespread problem in the poultry industry, and vaccination is the primary preventive method. However, moderately virulent vaccines may damage the bursa, necessitating the development of a safe and effective vaccine. The Newcastle disease virus (NDV) has been explored as a vector for vaccine development. In this study, reverse genetic technology was used to obtain three recombinant viruses, namely, rClone30-VP2L (P/M)-chGM-CSF (NP), rClone30-chGM-CSF (P/M)-VP2L (NP), and rClone30-VP2L-chGM-CSF (P/M). Animal experiments showed that the three biological adjuvant bivalent vaccines effectively increased anti-NDV and anti-infectious bursal disease virus (IBDV) titres, enhancing both humoral and cellular immune responses in chickens without leading to any harm. Amongst the three biological adjuvant bivalent vaccines, the rClone30-chGM-CSF (P/M)-VP2L (NP) group had higher levels of anti-NDV antibodies at 14 days after the first immunization and stimulated a greater humoral immune response in 7-10 days. While, the rClone30-VP2L (P/M)-chGM-CSF (NP) group was the most effective in producing a higher level of IBDV antibody response. In conclusion, these three vaccines can induce immune responses more rapidly and effectively, streamline production processes, be cost-effective, and provide a new avenue for the development of Newcastle disease (ND) and IBD bivalent vaccines.

MeSH

Vaccines, Viruses, Infectious Bursal Disease Virus, Immunity, Virulence